Pfizer Inc. which can be found using ticker (PFE) now have 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $45.00 and $25.00 calculating the mean target share price we have $31.86. (at the time of writing). Now with the previous closing price of $26.36 this is indicating there is a potential upside of 20.9%. Also worth taking note is the 50 day moving average now sits at $26.89 and the 200 moving average now moves to $27.97. The company has a market capitalization of 151.37B. The price for the stock stands currently at: $26.71 USD
The potential market cap would be $182,965,051,068 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 35.61, revenue per share of $10.49 and a 3.31% return on assets.
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operates through two segments: Biopharma and PC1. Biopharma is engaged in the science-based biopharmaceutical business. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. The Company’s primary care products include Eliquis, Nurtec ODT/Vydura and the Premarin family; the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac and Trumenba; Comirnaty, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Eucrisa/Staquis and Cibinqo; the Vyndaqel family, Oxbryta, BeneFIX and Genotropin, and Sulperazon, Medrol, Zavicefta, Zithromax, Vfend and Panzyga. Its oncology products include Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena and Braftovi.
